The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder
Abstract
We investigated the prevalence and clinical relevance of p53 nuclear overexpression, as detected by antibody PAb1801 and immunohistochemistry, in 33 patients with carcinoma in situ of the bladder. Median followup was 124 months. Disease progressed in 16 patients (48%) during followup. The association between p53 nuclear overexpression and tumor progression was assessed by multivariate analysis, controlling for possible confounding variables, such as patient age and sex, presence of associated stage Ta bladder tumor and adjuvant bacillus Calmette-Guerin therapy. Patients were stratified into 2 groups according to the per cent of tumor cells displaying p53 nuclear overexpression: group 1-18 with less than 20% tumor cells positive and group 2-15 with 20% or more tumor cells positive. Disease progressed in 3 patients (16.7%) in group 1 and in 13 (86.7%) in group 2 (p < 0.0001). Detection of p53 nuclear overexpression in 20% or more tumor cells was the only independent marker of tumor progression in univariate and multivariate analyses (p = 0.004, adjusted relative risk 8.6, 95% confidence interval 2 to 40). Death specifically from bladder cancer was also associated with this altered pattern of p53 expression (p = 0.01, Fisher's exact test). We conclude that p53 nuclear overexpression is an early event in bladder cancer, occurring in 48% of cases of carcinoma in situ of the bladder. Our results also suggest that p53 nuclear overexpression offers significant clinical information and may be a useful tool in the selection of therapy for patients with carcinoma in situ of the bladder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Cited by
Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., & Bergh, J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.173 · Cited by 381
Inactivation of p53 and Pten promotes invasive bladder cancer
Puzio-Kuter, A. M., Castillo-Martin, M., Kinkade, C. W., Wang, X., Shen, T. H., Matos, T., Shen, M. M., Cordon-Cardo, C., & Abate-Shen, C. (2009) · Genes & Development · doi:10.1101/gad.1772909 · Cited by 329
Self-citationP53 as a prognostic marker for bladder cancer: a meta-analysis and review
Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70315-6 · Cited by 317
Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C., & Scher, H. I. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1384 · Cited by 254
Self-citation
Metadata
- Authors
- Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E.
- Venue
- Journal of Urology
- Published
- 1994-08
- Volume
- 152
- Issue
- 2 Part 1
- Pages
- 388-392
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2410257367
- Cited by
- 211
- References
- 2
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder. https://app.cochat.ai/papers/10.1016/s0022-5347(17)32745-3
- The paper
- Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E. (1994). Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder. Journal of Urology. https://doi.org/10.1016/s0022-5347(17)32745-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.